Can Mounjaro Give You Diabetes — or Does It Work the Other Way?

You've read that Mounjaro affects insulin, so the worry makes sense

It's one of the most common questions our prescribers hear: if Mounjaro changes how the body handles insulin, could it tip someone into diabetes? The concern usually comes from people who have heard that tirzepatide is a diabetes drug and assumed the connection must run in both directions. It doesn't, and our dedicated page explains exactly why that assumption doesn't hold up.

Tirzepatide activates two receptors (GIP and GLP-1) that signal the pancreas to release insulin only when blood sugar is actually elevated. This glucose-dependent mechanism is precisely why it treats type 2 diabetes: it helps the body respond more appropriately to meals. Mounjaro's mechanism is covered in detail on our overview page, but the short version is that it restores signalling that obesity and insulin resistance tend to disrupt, rather than creating new dysfunction. In clinical trials, participants with prediabetes who took tirzepatide showed improvements in fasting glucose, not deterioration. The NHS's own tirzepatide guidance makes clear that hypoglycaemia (low blood sugar, not high) is the glycaemic risk worth watching in people who don't have diabetes.

So the misconception is a natural one, and letting it go means you can focus on the questions that actually matter for your situation.

When Mounjaro and blood sugar do need careful watching

There are two distinct scenarios where the relationship between Mounjaro and blood sugar deserves real attention.

The first is for people who already have type 2 diabetes and take other glucose-lowering medicines alongside tirzepatide. Adding a GIP/GLP-1 agonist on top of, say, a sulfonylurea or insulin can push blood sugar lower than intended. That isn't Mounjaro giving someone diabetes (it's the opposite) but it does require a prescriber to review and potentially adjust existing medication. If this applies to you, the page on using Mounjaro with type 2 diabetes covers the clinical picture in full.

The second scenario is pancreatitis. The pancreas produces both digestive enzymes and insulin, and there is a documented association between the GLP-1 class of medicines and acute pancreatitis, an uncommon but potentially serious inflammation. The MHRA issued a Drug Safety Update in January 2026 specifically flagging this risk and advising patients to seek urgent help for severe, persistent stomach pain that radiates to the back. Chronic pancreatitis, in turn, can impair insulin production over time. This is a plausible indirect pathway worth knowing about (though the absolute risk is low) and it is one reason a history of pancreatitis is a conversation to have with your prescriber before starting treatment. Mounjaro is generally not recommended if you have had repeated episodes.

What the evidence shows for people with prediabetes specifically

Some people asking this question are in a particular situation: they've been told their HbA1c is in the prediabetes range and they're wondering whether Mounjaro might push them over the threshold. The evidence runs in the other direction. In the SURMOUNT-1 trial, published in the New England Journal of Medicine, a substantial proportion of participants with prediabetes at baseline had returned to normal glucose levels by the end of the 72-week study period at the highest doses. Weight loss itself drives that improvement, and significant weight reduction through any means tends to reduce diabetes risk.

That doesn't mean Mounjaro is prescribed specifically to reverse prediabetes in the UK; the weight-management licence governs that use. But for people with a BMI of 27 or above and a weight-related condition such as impaired glucose tolerance, prediabetes is typically one of the qualifying factors that a prescriber weighs in your favour. If you have been diagnosed with type 2 diabetes and want to understand how tirzepatide fits into that picture, our page on Mounjaro for type 2 diabetes sets out the clinical detail. More on Mounjaro and diabetes is available if you want to explore the connection in more depth.

Who to talk to, and what to mention

If you have any personal or family history involving blood sugar (type 2 diabetes, prediabetes, gestational diabetes, polycystic ovary syndrome, or insulin resistance) tell your prescriber at the consultation stage. None of these necessarily rules Mounjaro out; several make it a stronger candidate. What they do change is how carefully your prescriber will calibrate the plan and, if you are on any existing glucose-lowering medicine, whether adjustments are needed first.

Mounjaro is not suitable during pregnancy, breastfeeding, or when actively trying to conceive, if any of these apply, raise this directly. People under 18 are outside the licensed age range. For anyone with a history of medullary thyroid carcinoma or MEN2 syndrome, these are absolute contraindications to discuss with your specialist, not an online pharmacy. If you've also seen questions circulating about whether Mounjaro can cause a kidney infection, our page on whether Mounjaro can cause a kidney infection addresses that concern clearly.

A real clinician reads every consultation at nume, a named, GPhC-registered Independent Prescriber assesses your answers the same day. If there is any uncertainty about whether your glucose history makes Mounjaro appropriate, they will tell you. You can also explore our frequently asked questions for more on the consultation process, or get in touch with our team directly. If you're ready to find out whether you're a candidate, start your free consultation and our prescribers will review your full picture.